Greene Co. gets approved for tornado assistance
Residents still in need after tornado
On an SBA Agency Declaration, counties are eligible to apply for physical damage disaster loans for homes and businesses and economic injury disaster loans for businesses. Brown, Jackson, Lawrence, Morgan and Owen Counties have also received the SBA Agency Declaration.
A Disaster Loan Outreach Center will be in Sherwood Oaks Christian Church, 2700 E Roger Rd, Bloomington, Indiana. Axe said they are prepared to open as early as Tuesday, June 3 if the state agrees.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating
Inc. (NASDAQ:JD) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 14, Citi analyst Alicia Yap raised the firm's price target on Inc. (NASDAQ:JD) from $42 to $44, while maintaining a Buy rating on the stock. The improved sentiment for the company follows its announcement of robust fiscal second-quarter 2025 results. Inc. (NASDAQ:JD) delivered RMB356.7 billion in revenue for the quarter, up 22.4% year-over-year, exceeding Wall Street estimates. Management noted that its Retail segment showed solid performance with revenue growing 20.6% and operating margins improving 4.5%. This was its highest margin in any promotional quarter. A wide and imposing view of a supply chain distribution center, illustrating the company's technology capabilities. Inc. (NASDAQ:JD) is an e-commerce company operating through its retail mobile apps and website, offering online retail and marketplace services. While we acknowledge the potential of JD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
43 minutes ago
- Yahoo
Robinhood Markets, Inc. (HOOD): 'The Numbers Are Extraordinary,' Says Jim Cramer
We recently published . Robinhood Markets, Inc. (NASDAQ:HOOD) is one of the stocks Jim Cramer recently discussed. Digital exchange Robinhood Markets, Inc. (NASDAQ:HOOD) is one of Cramer's favorite stocks. He believes that the firm enjoys a significant advantage over traditional brokers and has a strong platform that has facilitated the transfer of wealth between the older and younger generations. Robinhood Markets, Inc. (NASDAQ:HOOD)'s shares have gained 189% year-to-date as investors continue to be enthused about its competitive advantage and market share. Here are Cramer's latest comments about the firm: 'And you know that from Robinhood, the numbers are extraordinary. A lot of the brokers I think are sitting back, they don't want to admit it on air and say, oh my god, Robinhood is crushing us. 'Uh, I do think that, Vlad Tenev has got the brokers of the future. And I think that the other guys have to catch up.' Cryptocurrency Ethereum – Mobile device neo-broker smart stock trading app Previously, the CNBC TV host discussed Robinhood Markets, Inc. (NASDAQ:HOOD)'s platform: 'Do I have to describe Robinhood to you? It's an app. No, it's a bank. No, it's a repository of wealth of the millennials, whatever you want to call it. Robinhood has 25 million accounts, and it offers ETFs, options, gold, and crypto. It came out of nowhere. This company was worth $11 billion two years ago. Now it's $88 billion. Again, incredibly profitable. Out of nowhere, it seems to have captured young people who would otherwise not bother to invest. You know what I say? Hallelujah.' While we acknowledge the potential of HOOD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics, Inc. (RLAY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Relay Therapeutics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. For Relay Therapeutics, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of Earnings Estimate Revisions Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . Earnings Estimate Revisions for Relay Therapeutics For the fiscal year ending December 2025, this company is expected to earn -$1.73 per share, which is unchanged compared with the year-ago reported number. Analysts have been steadily raising their estimates for Relay Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.6%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Relay Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Relay Therapeutics, Inc. (RLAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
